Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A3384 in Bile Acid Malabsorption
NCT02078856Phase 2Completed
- Sponsor
- Albireo Pharma
- Start
- Mar 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of A3384 in bile acid malabsorption (BAM) (3 arms), sponsored by Albireo Pharma. Primary endpoint: Number of bowel movements at 2 weeks. Started Mar 2014; status: completed.
02
Drugs
A3384
03
Conditions
bile acid malabsorption (BAM)
Beyond the preview
Go deeper on NCT02078856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078856.